Glenmark licenses pain compound to Sanofi-Aventis
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis will develop and commercialise Glenmark's transient receptor potential vanilloid (TRPV3) antagonist molecules to treat chronic pain, under a licensing agreement between the two companies.